Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar Magnesium in Severe Hypertriglyceridemia
NCT03097107Phase 2Suspended
- Sponsor
- Zydus Therapeutics
- Start
- Apr 2017
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saroglitazar magnesium in hypertriglyceridemia, sponsored by Zydus Therapeutics. Started Apr 2017; status: suspended.
02
Drugs
saroglitazar magnesium
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03097107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097107.